A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2006
12/14/2006	WO2006132042A1 Nutritional supplement powder and fat for food or medicine
12/14/2006	WO2006131963A1 Method of modifying pectin and application thereof
12/14/2006	WO2006131923A2 Novel salts of conjugated psychotropic drugs and processes of preparing same
12/14/2006	WO2006131721A2 Topical ungual formulations
12/14/2006	WO2006131515A2 Stabilised il-21 compositions
12/14/2006	WO2006131401A2 Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
12/14/2006	WO2006130978A1 Polymer-based serum albumin substitute
12/14/2006	WO2006130949A1 Anti amyloid-related disease molecules and their uses
12/14/2006	WO2006130943A1 Respirable dried powder formulation comprising drug loaded nanoparticles
12/14/2006	WO2006105173A3 Oral delivery vehicle and material
12/14/2006	WO2006096970A8 Synthetic anti-candida albicans oligosaccharide based vaccines
12/14/2006	WO2006092727A9 Process for the production of calcium compositions in a continuous fluid bed
12/14/2006	WO2006075932A3 Remedy to accelerate healing of wound and burn
12/14/2006	WO2005105035A3 Targeted nanoparticles for drug delivery
12/14/2006	US20060281937 Stearate composition and method
12/14/2006	US20060281887 (Meth)acrylate copolymer for use as medical carrier
12/14/2006	US20060281706 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral
12/14/2006	US20060281175 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
12/14/2006	US20060281125 ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
12/14/2006	US20060281087 Titanium dioxide complex having molecule distinguishability
12/14/2006	US20060280784 amphiphilic substance or a hydrophobic substance is modified with a glycerol derivative, which is useful as a surface modifier for producing a drug carrier; liposome, a fat emulsion, an emulsion, a micell and a fine particle crystal
12/14/2006	US20060280782 Dermal delivery system composition comprising an aqueous base vehicle including Emu oil, at least one fatty acid alkyl ester, polyethylene glycol, and a gelling agent, in combination with a therapeutically effective amount of at least one species of insulin
12/14/2006	US20060280779 Phosphatidylserine enriched milk fractions for the formulation of functional foods
12/14/2006	US20060280778 Homeopathic Teething Pain Relief Composition and Method
12/14/2006	US20060280756 Novel composition
12/14/2006	US20060280749 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
12/14/2006	US20060280736 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/14/2006	US20060280735 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/14/2006	US20060280715 Retinoid solutions and formulations made therefrom
12/14/2006	US20060280692 A condensation aerosol for delivery of olanzapine by heating a compositionof olanzapine coated on a solid support to vaporize and condense; the vapor comprising particles of >10 percent by weight of olanzapine and <5 percent by weight of olanzapine degradation products; aerodynamic diameter=<5 microns
12/14/2006	US20060280690 Methods of preparing a foam comprising a sclerosing agent
12/14/2006	US20060280430 Method for delivering particulate drugs to tissues
12/14/2006	CA2653541A1 Polymer-based serum albumin substitute
12/14/2006	CA2611726A1 Pharmaceutical compositions containing sc(fv)2
12/14/2006	CA2611724A1 Stabilized milnacipran formulation
12/14/2006	CA2611451A1 Solid preparation
12/14/2006	CA2611200A1 Stabilised il-21 compositions
12/14/2006	CA2610987A1 Stabilizer for protein preparation comprising meglumine and use thereof
12/14/2006	CA2610881A1 Eye drop containing roflumilast
12/14/2006	CA2610838A1 Novel salts of conjugated psychotropic drugs and processes of preparing same
12/14/2006	CA2610755A1 Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
12/14/2006	CA2610605A1 Topical ungual formulations
12/14/2006	CA2610465A1 Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
12/14/2006	CA2610342A1 Sugar-coated tablet
12/13/2006	EP1731615A1 Cytoplasmic localization dna and rna
12/13/2006	EP1731174A2 Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
12/13/2006	EP1731173A1 Complex particles and coated complex particles
12/13/2006	EP1731172A1 Liposome preparation
12/13/2006	EP1731168A1 Antibody drug
12/13/2006	EP1731151A1 Solid pharmaceutical preparation containing sparingly water-soluble drug
12/13/2006	EP1731150A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof
12/13/2006	EP1731147A1 External preparation
12/13/2006	EP1731143A1 Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
12/13/2006	EP1731140A2 Medicinal aerosol formulation
12/13/2006	EP1731139A1 S/o type pharmaceutical preparation and process for producing the same
12/13/2006	EP1731138A1 Fine dispersion of sparingly soluble drug and process for producing the same
12/13/2006	EP1731134A1 Functional powders
12/13/2006	EP1731133A1 Composition containing a prepolymer and a crosslinker, process for producing and use thereof
12/13/2006	EP1730290A2 Compositions and methods for biodegradable polymer-peptide mediated transfection
12/13/2006	EP1730289A2 Method and products for the selective degradation of proteins
12/13/2006	EP1730216A1 Pseudo-thermosetting neutralized chitosan composition forming a hydrogel and a process for producing the same
12/13/2006	EP1730207A1 Compositions and methods for protecting materials from damage
12/13/2006	EP1730199A1 Native plant cell wall compositions and methods of use
12/13/2006	EP1730194A2 Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof
12/13/2006	EP1730174A1 Peptide carrier for drug delivery
12/13/2006	EP1730169A2 Metal-containing nanolayered composites, and applications thereof
12/13/2006	EP1730077A1 Embolization
12/13/2006	EP1729849A2 Implantable system for controlling gene expression
12/13/2006	EP1729823A2 Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
12/13/2006	EP1729821A2 Compositions and methods for topical application and transdermal delivery of botulinum toxins
12/13/2006	EP1729815A2 Pegylated ion channel modulating compounds
12/13/2006	EP1729814A2 Pegylated ion channel modulating compounds
12/13/2006	EP1729813A2 Inclusion complexes obtained by using a process with supercritical co2 and an agent for interaction with the complex
12/13/2006	EP1729812A1 Stable pharmaceutical composition comprising an ace inhibitor
12/13/2006	EP1729811A1 Cream-gel containing ivermectin
12/13/2006	EP1729810A2 Methods of reducing aggregation of il-1ra
12/13/2006	EP1729809A2 Dietary supplement and method for treating digestive system-related disorders
12/13/2006	EP1729794A1 A pharmaceutical composition comprising an active principle and sulphobetaine
12/13/2006	EP1729778A2 Pharmaceutical preparation containing drospirenone for application to the skin
12/13/2006	EP1729769A1 Compositions with reduced hepatotoxicity
12/13/2006	EP1729732A1 Anionic hyrdogel matrices with ph dependent modified release as drug carriers
12/13/2006	EP1729724A1 Inhalent formulation containing sulfoalkyl ether gamma-cyclodextryn and corticosteroid
12/13/2006	EP1549355B1 Method for the identification of sentinel lymph nodes
12/13/2006	EP1478372B1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
12/13/2006	EP1397132A4 Pirenzepine ophthalmic gel
12/13/2006	EP1328252B1 Transdermal pharmaceutical delivery composition
12/13/2006	EP1326599B1 Use of aivlosin for treating or preventing Lawsonia infections in pigs.
12/13/2006	EP1289487B1 Pre-formed sheet devices suitable for topical application
12/13/2006	EP1272531B1 Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
12/13/2006	EP1268836B1 Non-human sperm-dna complexes for genetically modifying non-human animals
12/13/2006	EP1143989B1 Exendins for glucagon suppression
12/13/2006	EP1143896B1 Methods of hydrating the nasal mucosal surface
12/13/2006	EP1093468B1 Polymers for delivering nitric oxide in vivo
12/13/2006	EP1024836B1 Compositions for delivering genes to antigen presenting cells of the skin
12/13/2006	EP0678035B9 Vaccine preparations
12/13/2006	CN1879065A Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
12/13/2006	CN1878824A Tri-block copolymers and a process for the preparation of the same
12/13/2006	CN1878602A Manufacturing method of organic compound particulate
12/13/2006	CN1878571A Polysaccharide-containing composition and lacrimal fluid layer-stabilizing instillation
12/13/2006	CN1878570A Stable pharmaceutical composition comprising granulocyte-colony stimulating factor

1 ... 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 ... 1712